The aim of the current study is to compare weekly versus three-week collective of carboplatin/paclitaxel in advanced epithelial ovarian cancer. The author's hypothesis was to study and correlate routine laboratory tests, clinical biomarkers and quality of life questionnaires between weekly and three-week standard carboplatin regimens in order to reveal any possible superiority for the weekly study arm.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Routine blood work and tumor markers
Timeframe: 6 cycles for each patient with a total of126 days
Additional kidney and anemia biomarkers
Timeframe: 6 cycles for each patient with a total of126 days
Improved quality of life
Timeframe: 6 cycles for each patient with a total of126 days